Retatrutide (GLP-3) — Triple-Agonist Metabolic Research Compound

Retatrutide represents a new frontier in metabolic and weight management research — a cutting-edge, multi-agonist peptide designed to activate GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor synergy has made Retatrutide a focal point in studies exploring fat loss, metabolic enhancement, and total body recomposition.

• Advanced Fat Loss Mechanisms – Retatrutide has been studied for its ability to significantly reduce body fat by enhancing satiety, slowing gastric emptying, and improving overall caloric efficiency. Research suggests it may promote sustained fat oxidation and long-term weight management through triple receptor activation.
• Muscle Preservation and Energy Regulation – Studies indicate that Retatrutide helps preserve lean muscle mass during caloric deficits by improving metabolic flexibility and energy balance — supporting a leaner, more efficient physique.
• Glucose and Insulin Optimization – By mimicking and enhancing natural incretin signaling (GLP-1 and GIP), Retatrutide has been shown to improve insulin sensitivity, regulate blood glucose levels, and support healthy metabolic function.
• Cardiometabolic Health and Longevity – Research has explored Retatrutide’s potential to improve lipid profiles, reduce inflammation, and support cardiovascular function — key components in long-term health and vitality.

Together, these mechanisms define Retatrutide as a Legendary peptide for metabolic mastery and body transformation — inspiring researchers to explore the boundaries of fat loss, energy regulation, and holistic metabolic renewal.

Retatrutide — triple-pathway investigational peptide (GLP-1, GIP, glucagon)
Tirzepatide — dual-pathway peptide model (GIP + GLP-1)
Semaglutide — single-pathway GLP-1 receptor model

For Research Use Only. Not for Human Consumption.